


Figure S1



First patient in: June 2015, Last patient in: December 2016, Data cutoff: January 2019

BIOMARK study schema: This study treatment consisted of two parts: the postoperative “primary therapy” and bevacizumab (BEV) beyond progression (BBP) as the “secondary therapy” given serially upon first progression. The primary therapy included three phases: a concurrent phase (temozolomide, radiation therapy, and bevacizumab), maintenance phase (up to 12 cycles of temozolomide and bevacizumab), and monotherapy phase (bevacizumab only until progression). The secondary therapy was given as bevacizumab monotherapy or in combination with other chemotherapeutic agents.